1. miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non- small Cell Lung Cancer 
Kristen M. Foss, BS, Chao Sima, PhD, Donatella Ugolini, BS, Monica Neri, PhD, Kristi E. Allen, BS, Glen J. Weiss, MD 
Journal of Thoracic Oncology 
Volume 6, Issue 3, Pages (March 2011)
DOI: /JTO.0b013e318208c785
Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
miR-1254 and miR-574-5p receiver operating characteristic (ROC) curve for discovery cohort. Quantitative polymerase chain reaction (qPCR) expression of miR-1254 and miR-574-5p was best able to stratify patients with early-stage non-small cell lung cancer (NSCLC) from controls with an area under the curve (AUC) of 0.77 and a 82% and 77% of sensitivity and specificity, respectively. Data were normalized to expression of cel-miR-39.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e318208c785)
Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
miR-1254 and miR-574-5p receiver operating characteristic (ROC) curve for validation cohort. Curves were generated from quantitative polymerase chain reaction (qPCR) microRNA (miRNA) data normalized to cel-miR-39. Stratification of early-stage non-small cell lung cancer (NSCLC) and controls was achieved with a sensitivity and specificity of 73% and 71%, respectively. The area under the curve (AUC) is 0.75, and the model is correctly classified for 16 of 22 NSCLC cases and 22 of 31 control cases.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e318208c785)
Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions